Refractory Enteropathy-Associated T-Cell Lymphoma
5 clinical trials · Condition
◉ Watch Refractory Enteropathy-Associated T-Cell Lymphoma
| Record | Firm | Date |
|---|---|---|
| Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas (NCT03598998) | City of Hope Medical Center | 2019-02-04 |
| Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (NCT03075553) | Mayo Clinic | 2017-05-17 |
| Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma (NCT01590732) | M.D. Anderson Cancer Center | 2012-10-29 |
Track Refractory Enteropathy-Associated T-Cell Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.